Japan Uterine Cancer Market Size & Outlook, 2025-2033


Japan Uterine Cancer Market Insights

  • As per Reed Intelligence insights, the Japan Uterine Cancer Market stood at USD 135.29 Million in 2024 and is anticipated to grow to USD 210.61 Million by 2033.
  • The Japan market is expected to advance at a CAGR of 5.01% from 2026 through 2033.
  • In 2024, Endometrial Adenocarcinoma accounted for the highest share of the By Type market size.
  • During the forecast period, Adenosquamous Carcinoma is set to register the highest growth, making it the most lucrative By Type segment.

Other Key Findings


  • In 2024, Japan accounted for 2.16% of the global Uterine Cancer Market size.
  • By 2033, United States is expected to lead the global Uterine Cancer Market in terms of market size.
  • Within Asia Pacific, China is projected to dominate the regional Uterine Cancer Market size by 2033.
  • South Korea is identified as the fastest-growing market in Asia Pacific, anticipated to reach USD 82.51 Million by 2033.

Report Summary

Report Scope Details
Base Year for Study 2024
Study Period 2021-2033
Historical Period 2021-2023
Forecast Period 2025-2033
Market Size In 2024 USD 135.29 Million
Market Size In 2033 USD 210.61 Million
Largest segment Endometrial Adenocarcinoma
Units Revenue in USD Million
CAGR 5.01% (2025-2033)
Segmnetation Covered
By Type
  1. Endometrial Adenocarcinoma
  2. Adenosquamous Carcinoma
  3. Papillary Serous Carcinoma
  4. Uterine Sarcoma
By Treatment
  1. Diagnosis
  2. Therapeutic Treatment
  3. Surgery
By End-Users
  1. Hospitals
  2. Diagnostic Centers
  3. Drug Stores
  4. Online Pharmacies
  5. Other End Users
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends